The Drug That May Redefine What's Possible

Retatrutide may be the first pharmacotherapy to approach bariatric surgery–level weight loss. Phase 3 data now confirm what phase 2 only suggested: this is a categorically different molecule.

The Peptide Wild West (Part II)

The compounds with almost no human data — and one with an active safety signal. Plus the full scorecard and what to actually make of all this.

The Peptide Wild West (Part I)

RFK Jr. wants to unlock 14 banned compounds. Before you inject one, here's what the human evidence actually says.

SPECIAL EDITION: I've Been Taking Low-Dose Tirzepatide for Two Years. Here's What I've Learned.

A physician's honest account of off-label self-experimentation — and why I don't recommend you follow my lead.

Why Weight Returns After Stopping GLP-1 Therapy: The Biology You Need to Understand

Across randomized trials, stopping GLP-1/dual incretin therapy is typically followed by clinically meaningful weight regain and loss of cardiometabolic gains—often within months—highlighting obesity as a chronic, relapsing condition.

Why Obesity Is Not a Choice

The neuroscience and evolutionary biology behind a widely misunderstood disease

Obesity Care: Past, Present, and Future

How history can inform a more equitable future.

Beyond Blame: Reclaiming Nuance in Our Understanding of Obesity

Appetite, Food Noise, and What We've Been Getting Wrong

The GLP1 Problem